Vertex Pharma Is 'Hyped,' H.C. Wainwright Sees 35% Downside
July 06, 2015 at 08:34 AM EDT
In a report published Monday, H.C. Wainwright analyst Andrew S. Fein maintained a Neutral rating and $85 price target on Vertex ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.